Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Return on equity
Regeneron Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 June 2026 was 14.0%, down 0.8 percentage points from fiscal 2025 (14.9%). Over the past ten years it has ranged from 14.9% (fiscal 2025) to 54.2% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −56.4% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 14.9% | (1.08) |
| FY2024 | 16.0% | (0.31) |
| FY2023 | 16.3% | (4.68) |
| FY2022 | 20.9% | (33.27) |
| FY2021 | 54.2% | 22.44 |
| FY2020 | 31.8% | 10.45 |
| FY2019 | 21.3% | (11.49) |
| FY2018 | 32.8% | 10.18 |
| FY2017 | 22.6% | 0.53 |
| FY2016 | 22.1% | 1.60 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 96.6% |
| ARGX argenex SE compare | 27.1% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 23.5% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 14.7% |
| REGN Regeneron Pharmaceuticals, Inc. | 14.0% |
| RPRX Royalty Pharma PLC compare | 8.42% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| MRNA Moderna, Inc. compare | −39.0% |
| RVMD Revolution Medicines, Inc. compare | −79.1% |
| Biotechnology industry median | −56.4% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement